TearScience, a Morrisville, N.C.-based medical device company, completed its Series D funding.
The name of the backers and amount of the deal were not disclosed.
Led by Joseph Boorady, President and CEO, TearScience is a medical device company and manufacturer of LipiView and LipiFlow for the treatment of meibomian gland dysfunction (MGD), a progressive, obstructive disease and a root cause of dry eye, distinguished by loss of function and structure of tear oil glands.
LipiView II with Dynamic Meibomian Imaging™ (DMI) distinctively images meibomian gland structure. The Korb Meibomian Gland Evaluator™ assists physicians to reproducibly assess gland function. LipiFlow uses Vectored Thermal Pulse™ (VTP) technology to precisely direct inner-lid treatment and has received clearance by the US Food and Drug Administration for use in patients with MGD.